Research programme: stem cell therapeutics - BioRestorative Therapies

Drug Profile

Research programme: stem cell therapeutics - BioRestorative Therapies

Alternative Names: BRTX-100; brtxDISC; ThermoStem

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator BioRestorative Therapies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Diabetes mellitus; Hypertension; Intervertebral disc degeneration; Metabolic disorders; Obesity

Most Recent Events

  • 20 Apr 2017 BioRestorative Therapies has patents pending for covering methods related to methods of generating stem cells and stem cell lines from brown adipose tissue in Australia
  • 08 Feb 2017 The US FDA approves IND application for BRTX-100 in Intervertebral disc degeneration
  • 08 Feb 2017 BioRestorative Therapies plans a phase II trial for BRTX-100 in Intervertebral disc degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top